Day One Biopharmaceuticals, Inc.
DAWN
$21.31
$0.020.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.92% | -57.56% | 313.92% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.92% | -57.56% | 313.92% | -- | -- |
| Cost of Revenue | 103.92% | 181.76% | 432.53% | -- | -- |
| Gross Profit | 81.64% | -61.69% | 302.71% | -- | -- |
| SG&A Expenses | 14.84% | -2.85% | -4.03% | 10.42% | 34.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.14% | -0.12% | -44.00% | 16.29% | 58.85% |
| Operating Income | 57.97% | -181.83% | 69.54% | 33.51% | -9.77% |
| Income Before Tax | 60.75% | -154.56% | -962.07% | 42.33% | -8.68% |
| Income Tax Expenses | -130.52% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 67.62% | -153.26% | -588.04% | 42.33% | -20.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.62% | -153.26% | -588.04% | 42.33% | -20.55% |
| EBIT | 57.97% | -181.83% | 69.54% | 33.51% | -9.77% |
| EBITDA | 58.94% | -177.27% | 70.23% | 34.81% | -8.75% |
| EPS Basic | 70.26% | -149.78% | -481.42% | 51.32% | -1.26% |
| Normalized Basic EPS | -- | -151.00% | -797.07% | 47.10% | 8.71% |
| EPS Diluted | 70.27% | -150.21% | -481.42% | 51.32% | -0.99% |
| Normalized Diluted EPS | -- | -151.18% | -797.07% | 47.10% | 8.71% |
| Average Basic Shares Outstanding | -- | 6.99% | 18.31% | 18.49% | 19.06% |
| Average Diluted Shares Outstanding | 0.92% | 6.65% | 18.31% | 18.49% | 19.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |